A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC
一项针对EGFR突变、PD-L1阳性、未接受过酪氨酸激酶抑制剂治疗的晚期非小细胞肺癌患者的帕博利珠单抗II期研究
期刊:Journal of Thoracic Oncology
影响因子:20.8
doi:10.1016/j.jtho.2018.03.035
Lisberg, A; Cummings, A; Goldman, J W; Bornazyan, K; Reese, N; Wang, T; Coluzzi, P; Ledezma, B; Mendenhall, M; Hunt, J; Wolf, B; Jones, B; Madrigal, J; Horton, J; Spiegel, M; Carroll, J; Gukasyan, J; Williams, T; Sauer, L; Wells, C; Hardy, A; Linares, P; Lim, C; Ma, L; Adame, C; Garon, Edward B
肺癌
肿瘤
肿瘤免疫
信号转导
EGF
PD-L1
EGFR
细胞生物学